In ACT, terminally differentiated CD45RA+ CCR7− T effector-like cells (TEff cells) demonstrated enhanced in vitro anti-tumor activity, whereas in vivo T cell activation, proliferative capacity, and persistence were impaired [14]. This evidence concerns the gene CCR7 and neoplasm.